

# BV6

Inhibitor of IAPs (inhibitor of apoptosis proteins) - InvitroFit™

Catalog code: inh-bv6

<https://www.invivogen.com/bv6>

For research use only

Version 23118-MM

## PRODUCT INFORMATION

### Contents

- 5 mg BV6 - InvitroFit™

### Storage and stability

- BV6 is provided as a powder and shipped at room temperature. Upon receipt, store at -20 °C.
- Upon resuspension, prepare aliquots and store at -20 °C. Resuspended product is stable for 6 months at -20 °C when properly stored. Avoid repeated freeze-thaw cycles.

### Quality control

- Purity: ≥95% (UHPLC)
- The inhibitory activity has been confirmed using in-house cellular assays.
- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.

## DESCRIPTION

BV6 is a potent and specific antagonist of three inhibitor of apoptosis proteins (IAPs), namely cIAP1, cIAP2, and XIAP<sup>1</sup>. IAPs exert their anti-apoptotic actions through ubiquitylation of RIPK1 (receptor-interacting serine/threonine-protein kinase 1), which results in RIPK1 proteasomal degradation<sup>2</sup>. The apoptosis initiator caspase, Caspase-8 (CASP-8), can no longer associate with RIPK1 and RIPK3, and thus remains non-activated<sup>3</sup>.

Smac/DIABLO (second mitochondria-derived activator of caspases/direct IAP-binding protein with low isoelectric point) is a natural antagonist of IAPs, which is released in the cytosol in response to pro-apoptotic stimuli. BV6 acts as a Smac mimetic. Upon binding to select BIR (baculovirus IAP repeat) domains, BV6 induces auto-ubiquitination and rapid proteasomal degradation of cIAP, thus allowing for TNF- $\alpha$ -induced apoptosis or necroptosis<sup>1,4</sup>. Restoring and promoting cancer cell death using Smac mimetics are promising therapeutic strategies<sup>4,5</sup>.

1. Varfolomeev E. *et al.*, 2007. IAP antagonists induce autoubiquitination of c-IAPs, NF- $\kappa$ B Activation, and TNF $\alpha$ -dependent apoptosis. *Cell*. 131(4):669-681. 2. Annibaldi A. *et al.*, 2018. Ubiquitin-mediated regulation of RIPK1 kinase activity independent of IKK and MK2. *Molecular Cell*. 69:566-580. 3. Choi M.E. *et al.*, 2019. Necroptosis: a crucial pathogenic mediator of human disease. *JCI Insight*. 4(15):e128834. 4. Li W. *et al.*, 2011. BV6, an IAP antagonist, activates apoptosis and enhances radiosensitization of non-small cell lung carcinoma in vitro. *J. Thorac. Oncol.* 6(11), 1801-1809. 5. Schirmer M. *et al.*, 2016. Intrinsic and chemo-sensitizing activity of SMAC-mimetics on high-risk childhood acute lymphoblastic leukemia. *Cell Death Dis.* 7:e2052.

## CHEMICAL PROPERTIES

CAS number: 1001600-56-1


Synonyms: BV-6; N,N'-(hexane-1,6-diyl)bis(1-((2S)-2-cyclohexyl-2-[(N-methyl-L-alanyl)amino]acetyl)-L-prolyl-beta-phenyl-L-phenylalaninamide)

Formula: C<sub>70</sub>H<sub>96</sub>N<sub>10</sub>O<sub>8</sub>

Structure:

Molecular weight: 1205.6 g/mol

Solubility: 10 mg/ml (8.33 mM) in DMSO



## METHODS

### Preparation of stock solution (5 mM)

1. Add 833  $\mu$ l DMSO to 5 mg BV6 vial.
2. Vortex until completely resuspended.
3. Prepare aliquots of BV6 and store at -20 °C.
4. Once BV6 is resuspended, further dilutions can be prepared using sterile aqueous buffers.

Working concentration range: 0.3-5  $\mu$ M for cell culture assays

## PROTOCOL

Below is a protocol for measuring cell death using THP1-HMGB1-Lucia™ cells. This assay relies on the luminescence quantification of the HMGB1::Lucia fusion protein released in the supernatant upon pyroptosis or necroptosis. For more information, visit: <https://www.invivogen.com/thp1-hmgb1-lucia>.

### Necroptosis assay

It is recommended to perform the assay with test medium which does not contain Normocin™ nor Zeocin™.

1. Add 20  $\mu$ l of a caspase inhibitor such as Z-VAD-FMK (25  $\mu$ M final concentration) per well of a flat-bottom 96-well plate.
2. Prepare a THP1-HMGB1-Lucia™ suspension at  $\sim 2.5 \times 10^6$  cells/ml.
3. Dispense 120  $\mu$ l of cell suspension ( $\sim 300,000$  cells) per well.
4. Incubate at 37 °C in 5% CO<sub>2</sub> for 1 h.
5. Add 20  $\mu$ l of a cIAP inhibitor such as BV6 (5  $\mu$ M final concentration) and recombinant hTNF- $\alpha$  (100 ng/ml final concentration) per well.
6. Incubate the plate at 37 °C in a CO<sub>2</sub> incubator for 8-24 h. Proceed to detection of HMGB1::Lucia using QUANTI-Luc™ 4 Lucia/Gaussia as described on the next page.

## TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Asia: +852 3622-34-80

E-mail: [info@invivogen.com](mailto:info@invivogen.com)

 **InvivoGen**  
www.invivogen.com

### Detection of HMGB1::Lucia

Below is a protocol for end-point readings using a luminometer. This protocol can be adapted for use with kinetic measurements.

1. Prepare the [QUANTI-Luc™ 4 Lucia/Gaussia](#) assay solution following the instructions on the enclosed data sheet.
2. Transfer 10 µl of THP1-HMGB1-Lucia™ stimulated cell supernatant into a 96-well white (opaque) or black plate, or a luminometer tube.
3. Add 50 µl of [QUANTI-Luc™ 4 Lucia/Gaussia](#).
4. Proceed **immediately** with the measurement.

## RELATED PRODUCTS

Product	Description	Cat. Code
Necrostatin-1	RIPK1 inhibitor	inh-ncst1
Z-IETD-FMK	Caspase-8 inhibitor	inh-ietd
Z-VAD-FMK	Pan-caspase inhibitor	tlrl-vad
Recombinant hTNF-α	Recombinant cytokine	rcyc-htrnfa
THP1-HMGB1-Lucia™	Reporter cell line	thp-gb1lc
QUANTI-Luc™ 4 Lucia/Gaussia	Detection reagent	rep-qlc4lg1

---

#### TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873  
InvivoGen USA (International): +1 (858) 457-5873  
InvivoGen Europe: +33 (0) 5-62-71-69-39  
InvivoGen Asia: +852 3622-34-80  
E-mail: [info@invivogen.com](mailto:info@invivogen.com)